SynthesisWorld journal of surgical oncology2015
Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Colombian consensus for the molecular diagnosis of endometrial cancerRevista colombiana de obstetricia y ginecologia · 2024Guideline
- Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis.JCO precision oncology · 2026Article
- Molecular Profiling and Treatment Outcomes in Uterine Serous Carcinoma: Prognostic Role of Estrogen Receptor Expression.Current oncology (Toronto, Ont.) · 2026Article
- Obesity, Bariatric Surgery, and Cancer Risk: Nutritional Perspectives and Long-Term Clinical Implications.Nutrients · 2026Review
- Predictive value of immunohistochemical parameters combined with clinicopathological features in predicting recurrence after lymph node resection in endometrial cancer patients.American journal of translational research · 2026Article
- Prognostic and predictive roles of microsatellite instability and mismatch repair deficiency in early-stage endometrial cancer: a structured narrative review.Obstetrics & gynecology science · 2026Review
- Risk Factors for the Prognosis of Endometrioid Endometrial Cancer: A Chinese Cohort Study.Obstetrics and gynecology international · 2026Article
- Unveiling Metabolic Subtypes in Endometrial Cancer Cell Lines: Insights from Metabolomic Analysis Under Standard and Stress Conditions.International journal of molecular sciences · 2025Article
- Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells · 2025Review
- An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer.Future oncology (London, England) · 2025Article
- Analysis of postoperative prognosis of non-metastatic endometrial carcinoma under different recurrence patterns.Scientific reports · 2025Article
- The Influence of the GermlineCancers · 2025Article
- Article
- microRNA profile of endometrial cancer from Indian patients-identification of potential biomarkers for prognosis.Biochemistry and biophysics reports · 2024Article
- Gold nanomaterials: important vectors in biosensing of breast cancer biomarkers.Analytical and bioanalytical chemistry · 2024Review
- Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy.Cancers · 2024Review
- In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Molecular cancer therapeutics · 2023Article
- Identification and Characterization of Metabolic Subtypes of Endometrial Cancer Using a Systems-Level Approach.Metabolites · 2023Article
- ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma.Facts, views & vision in ObGyn · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to summarize the global predicting role of hormone receptors for survival in endometrial cancer.
methodsEligible studies were identified and assessed for quality through multiple search strategies. Data were collected from studies comparing overall survival (OS), cancer-specific survival (CSS), or progression-free survival (PFS) in patients with elevated levels of estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) with those in patients with lower levels. The combined hazard ratios of ER, PR, and HER2 for survival were calculated.
resultsA total of 98 studies were included for meta-analysis (44 for ER, 38 for PR, and 16 for HER2). Higher levels of either ER or PR could significantly indicate better survival. The pooled hazard ratios (HRs) of ER for OS, CSS, and PFS were 0.75 (95% CI, 0.68-0.83), 0.45 (95% CI, 0.33-0.62), and 0.66 (95% CI, 0.52-0.85), respectively. The combined HRs of PR for OS, CSS, and PFS reached 0.63 (95% CI, 0.56-0.71), 0.62 (95% CI, 0.42-0.93), and 0.45 (95% CI, 0.30-0.68), respectively. In contrast, elevated levels of HER2 could predict worse outcome with a HR of 1.98 (95% CI, 1.49-2.62) for OS, and a HR of 2.26 (95% CI, 1.57-3.25) for PFS.
conclusionsIn patients with endometrial cancer, higher level of ER and PR predicted favorable survival, and increased level of HER2 was associated with poorer survival. All of the three hormone receptors had prognostic value for survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.